IL3RA
Interleukin-3 receptor subunit alpha
As of the edition of 20 October 2026, IL3RA (interleukin-3 receptor subunit alpha, UniProt P26951) has 10 drugs tested at it and 10 companies on the list, 5 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P26951
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 4
- Disease areas
- Blood and lymph; Cancer; Skin and connective tissue; Immune system; Infections; Heart and blood vessels; Inherited and neonatal
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Went quiet | 3 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tagraxofusp | Marketed | Phase 2 | Ends 2030 |
| Flotetuzumab | Stopped | Phase 2 | none listed |
| Pivekimab sunirine | Marketed | Phase 3 | Ends 2038 |
| Talacotuzumab | Went quiet | Phase 3 | none listed |
| AFM28 | Stopped | Phase 1 | none listed |
| AZD9829 | Status not established | Phase 2 | none listed |
| CSL-360 | Went quiet | Phase 1 | none listed |
| JNJ-63709178 | Went quiet | Phase 1 | none listed |
| KHK2823 | Stopped | Phase 1 | none listed |
| MGD024 | Active | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 3 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| Sanofi | Route A |
| Stemline Therapeutics | Route B |
The other 7 companies at IL3RA
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at IL3RA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.